EU Medtech Ecosystem Will Suffer Unless Notified Body Workload Concerns Are Addressed – The German View
Executive Summary
An EU notified body redesignation rate of 10 per year is too slow. It won't help small companies using the new Medical Device and IVD Regulation systems, and is leaving NBs feeling let down and with a mountain to climb. A German industry group weighs in on the need to speed up redesignations.
You may also be interested in...
Exec: EU May Lose Out On More Innovation As MDR Pressure On NBs Begins To Bite
The new MDR and IVDR were drafted with highest interests of EU patients in mind, but they may yet have a devastating effect on the EU's speedy access to innovation in general, and on medtech SMEs in particular. That is the view of one Swiss medtech CEO; he also has grave concerns about the loss of EU notified bodies and the impact on manufacturers.
Over 170 Provisional Draft Codes Published For Notified Body Designation Under MDR & IVDR
Three new draft documents relating to notified bodies list the codes being prepared to determine their scope of responsibility for designation under the new EU medtech regulations and the raft of documentation they will be asked to submit when they apply for redesignation.
With EU Notified Body Numbers Tumbling, How Do Manufacturers Ensure Seamless Transition To MDR?
Device manufacturers in the EU are beginning to realize the extra volume of MDR/IVDR-related work that their pivotal market access partners, the notified bodies, will have to take on. With the regulations' three- and five-year transition period clocks ticking down already, manufacturers must make sure that business continuity is guaranteed – but it won't be easy.